

# Atanu Bhattacharjee

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5151687/publications.pdf>

Version: 2024-02-01

108  
papers

1,361  
citations

623188

14  
h-index

395343

33  
g-index

110  
all docs

110  
docs citations

110  
times ranked

1779  
citing authors

#	ARTICLE	IF	CITATIONS
1	Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 124-136.	0.8	295
2	Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 1064-1072.	0.8	229
3	A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer. <i>Cancer</i> , 2019, 125, 3184-3197.	2.0	73
4	A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck. <i>Oral Oncology</i> , 2015, 51, 279-286.	0.8	65
5	Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial. <i>The Lancet Global Health</i> , 2020, 8, e1213-e1222.	2.9	57
6	Phase I/II Study of Palliative Triple Metronomic Chemotherapy in Platinum-Refractory/Early-Failure Oral Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 3032-3041.	0.8	51
7	Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma. <i>ESMO Open</i> , 2017, 2, e000168.	2.0	48
8	Salvage surgery in head and neck cancer: Does it improve outcomes?. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1052-1058.	0.5	25
9	SARS-CoV-2 reinfection after previous infection and vaccine breakthrough infection through the second wave of pandemic in India: An observational study. <i>International Journal of Infectious Diseases</i> , 2022, 118, 95-103.	1.5	24
10	Metronomic chemotherapy in platinum-insensitive failures and/or early failures postmultimodality management in oral cancers. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2015, 36, 161-165.	0.1	20
11	Expectations and preferences for palliative chemotherapy in head and neck cancers patients. <i>Oral Oncology</i> , 2016, 63, 10-15.	0.8	16
12	Clinical biomarker discovery by SWATH-MS based label-free quantitative proteomics: impact of criteria for identification of differentiators and data normalization method. <i>Journal of Translational Medicine</i> , 2019, 17, 184.	1.8	16
13	Reverse swing, phase 1 study of repurposing mebendazole in recurrent high-grade glioma. <i>Cancer Medicine</i> , 2020, 9, 4676-4685.	1.3	16
14	Identification of molecular descriptors for design of novel Isoalloxazine derivatives as potential Acetylcholinesterase inhibitors against Alzheimer's disease. <i>Journal of Biomolecular Structure and Dynamics</i> , 2017, 35, 1729-1742.	2.0	15
15	Aprepitant for Cough Suppression in Advanced Lung Cancer. <i>Chest</i> , 2020, 157, 1647-1655.	0.4	15
16	Effect of Early Palliative Care on Quality of Life of Advanced Head and Neck Cancer Patients: A Phase III Trial. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1228-1237.	3.0	14
17	When COVID-19 will decline in India? Prediction by combination of recovery and case load rate. <i>Clinical Epidemiology and Global Health</i> , 2021, 9, 17-20.	0.9	13
18	Application of Bayesian Approach in Cancer Clinical Trial. <i>World Journal of Oncology</i> , 2014, 5, 109-112.	0.6	13

#	ARTICLE	IF	CITATIONS
19	HER2 borderline is a negative prognostic factor for primary malignant breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 225-231.	1.1	12
20	Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer. <i>Oncotarget</i> , 2020, 11, 399-408.	0.8	12
21	An audit of the results of a triplet metronomic chemotherapy regimen incorporating a tyrosine kinase inhibitor in recurrent/metastatic head and neck cancers patients. <i>South Asian Journal of Cancer</i> , 2016, 05, 048-051.	0.2	12
22	Pilot study of single-day distress screening with the NCCN distress thermometer to evaluate the feasibility of routine distress screening in tertiary cancer center in rural India. <i>Psycho-Oncology</i> , 2015, 24, 832-834.	1.0	11
23	Results of a phase II randomized controlled clinical trial comparing efficacy of Cabazitaxel versus Docetaxel as second line or above therapy in recurrent head and neck cancer. <i>Oral Oncology</i> , 2017, 75, 54-60.	0.8	11
24	Parametric survival analysis using R: Illustration with lung cancer data. <i>Cancer Reports</i> , 2020, 3, e1210.	0.6	11
25	A tertiary care experience with paclitaxel and cetuximab as palliative chemotherapy in platinum sensitive and nonsensitive in head and neck cancers. <i>South Asian Journal of Cancer</i> , 2017, 06, 011-014.	0.2	11
26	Next generation metronomic chemotherapy—report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6–8 May 2016, Mumbai. <i>Ecancermedalscience</i> , 2016, 10, 689.	0.6	10
27	Bayesian state-space modeling in gene expression data analysis: An application with biomarker prediction. <i>Mathematical Biosciences</i> , 2018, 305, 96-101.	0.9	10
28	Comparison of the seventh and eighth editions American Joint Committee Cancer classification system in oral cavity squamous cell cancers. <i>International Journal of Cancer</i> , 2020, 146, 3379-3384.	2.3	10
29	Prognostic Impact of Pattern of Mandibular Involvement in Gingivo-Buccal Complex Squamous Cell Carcinomas: Marrow and Mandibular Canal Staging System. <i>Frontiers in Oncology</i> , 2021, 11, 752018.	1.3	10
30	Checkpoint inhibitor accessibility in 15,000+ Indian patients.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9012-9012.	0.8	10
31	Patterns of failure and outcomes in cT4 Oral squamous cell carcinoma (OSCC) undergoing upfront surgery in comparison to Neo-Adjuvant Chemotherapy (NACT) followed by surgery: A Matched Pair analysis. <i>Oral Oncology</i> , 2020, 100, 104455.	0.8	9
32	Human papillomavirus elevated genetic biomarker signature by statistical algorithm. <i>Journal of Cellular Physiology</i> , 2020, 235, 9922-9932.	2.0	9
33	Should we wait or not? The preferable option for patients with stage IV oral cancer in COVID-19 pandemic. <i>Head and Neck</i> , 2020, 42, 1173-1178.	0.9	9
34	Results of a randomized phase III study of nimotuzumab in combination with concurrent radiotherapy and cisplatin versus radiotherapy and cisplatin alone, in locally advanced squamous cell carcinoma of the head and neck.. <i>Journal of Clinical Oncology</i> , 2018, 36, 6000-6000.	0.8	9
35	Disease progression of cancer patients during COVID-19 pandemic: a comprehensive analytical strategy by time-dependent modelling. <i>BMC Medical Research Methodology</i> , 2020, 20, 209.	1.4	8
36	Locoregional recurrence after cystectomy in muscle invasive bladder cancer: Implications for adjuvant radiotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 496.e9-496.e15.	0.8	8

#	ARTICLE	IF	CITATIONS
37	Assay of urinary protein carbonyl content can predict the steroid dependence and resistance in children with idiopathic nephrotic syndrome. Saudi Journal of Kidney Diseases and Transplantation: an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2017, 28, 268.	0.4	8
38	Quality of life and quality-adjusted time without toxicity in palliatively treated head-and-neck cancer patients. South Asian Journal of Cancer, 2018, 07, 249-252.	0.2	8
39	Bayesian Competing Risks Model: An Application to Breast Cancer Clinical Trial with Incomplete Observations. Journal of Statistics and Management Systems, 2015, 18, 381-404.	0.3	7
40	Classification algorithm for high-dimensional protein markers in time-course data. Statistics in Medicine, 2020, 39, 4201-4217.	0.8	7
41	Soft tissue deposit in neck dissection specimen carries a poor prognosis in oral cancer: A matched pair analysis. Head and Neck, 2020, 42, 1783-1790.	0.9	7
42	Phase III Non-inferiority Study Evaluating Efficacy and Safety of Low Dose Gemcitabine Compared to Standard Dose Gemcitabine With Platinum in Advanced Squamous Lung Cancer. EClinicalMedicine, 2019, 9, 19-25.	3.2	6
43	Time-course data prediction for repeatedly measured gene expression. International Journal of Biomathematics, 2019, 12, 1950033.	1.5	6
44	Alcohol and cancer risk: A systematic review and meta-analysis of prospective Indian studies. Indian Journal of Public Health, 2020, 64, 186.	0.3	6
45	Results of phase 3 randomized trial for use of docetaxel as a radiosensitizer in patients with head and neck cancer unsuitable for cisplatin-based chemoradiation.. Journal of Clinical Oncology, 2022, 40, LBA6003-LBA6003.	0.8	6
46	Survey of the State of Implementation of the American Society of Clinical Oncology/Oncology Nursing Society Safety Standards for Chemotherapy Administration in India. Journal of Oncology Practice, 2015, 11, 365-369.	2.5	5
47	Neoadjuvant chemotherapy in geriatric head and neck cancers. Head and Neck, 2017, 39, 886-892.	0.9	5
48	Assay of urinary protein-bound sialic acid can differentiate steroidsensitive nephrotic syndrome from steroid-resistant cases. Saudi Journal of Kidney Diseases and Transplantation: an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2016, 27, 37.	0.4	5
49	Identification of key gene signatures for the overall survival of ovarian cancer. Journal of Ovarian Research, 2022, 15, 12.	1.3	5
50	Impact of thrombosis on standard treatment in solid tumors. Thrombosis Research, 2015, 136, 943-946.	0.8	4
51	Human epidermal growth factor receptor 2 borderline mortality in breast cancer patients: Evidence from surveillance, epidemiology, and end results program population-based study. Clinical Epidemiology and Global Health, 2018, 6, 88-93.	0.9	4
52	Determining an Optimum Biological Dose of A Metronomic Chemotherapy. Journal of Data Science, 2017, 15, 77-94.	0.5	4
53	Phase 3 randomised study evaluating the addition of low-dose nivolumab to palliative chemotherapy in head and neck cancer.. Journal of Clinical Oncology, 2022, 40, LBA6016-LBA6016.	0.8	4
54	Compliance With Neoadjuvant Chemotherapy in T4 Oral Cancers: Place, Person, Socioeconomic Status, or Assistance. Journal of Global Oncology, 2015, 1, 65-72.	0.5	3

#	ARTICLE	IF	CITATIONS
55	Impact of waiting time for treatment on survival in patients undergoing radiotherapy for head and neck cancer. <i>Journal of Cancer Policy</i> , 2017, 13, 1-4.	0.6	3
56	Survey of Implementation of Antiemetic Prescription Standards in Indian Oncology Practices and Its Adherence to the American Society of Clinical Oncology Antiemetic Clinical Guideline. <i>Journal of Global Oncology</i> , 2017, 3, 346-359.	0.5	3
57	A joint longitudinal and survival model for dynamic treatment regimes in Presence of Competing Risk Analysis. <i>Clinical Epidemiology and Global Health</i> , 2019, 7, 337-341.	0.9	3
58	Bayesian competing risks analysis without data stratification. <i>Clinical Epidemiology and Global Health</i> , 2020, 8, 265-270.	0.9	3
59	In silico molecular modelling, structural dynamics simulation and characterization of antifungal nature of $\beta$ -glucosidase enzyme from <i>Sechium edule</i> . <i>Journal of Biomolecular Structure and Dynamics</i> , 2020, 39, 1-9.	2.0	3
60	An impact of reduction in point prevalence of tobacco use on cancer incidence- A challenge for global policy makers. <i>Clinical Epidemiology and Global Health</i> , 2020, 8, 1287-1296.	0.9	3
61	The results of sequential swallowing assessments after total laryngectomy for laryngeal and hypopharyngeal malignancies. <i>European Archives of Oto-Rhino-Laryngology</i> , 2020, 277, 3469-3477.	0.8	3
62	Joint modeling of longitudinal and time-to-event data on multivariate protein biomarkers. <i>Journal of Computational and Applied Mathematics</i> , 2021, 381, 113016.	1.1	3
63	Illustration of missing data handling technique generated from hepatitis C induced hepatocellular carcinoma cohort study. <i>Journal of King Saud University - Science</i> , 2021, 33, 101403.	1.6	3
64	Critically ill patients with diabetes and Middle East respiratory syndrome: a multi-center observational study. <i>BMC Infectious Diseases</i> , 2021, 21, 84.	1.3	3
65	A selection modelling approach to analysing missing data of liver Cirrhosis patients. <i>Biometrical Letters</i> , 2016, 53, 83-103.	0.4	3
66	Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexed+carboplatin chemotherapy. <i>Ecancermedalscience</i> , 2017, 11, 776.	0.6	2
67	Expression signature of lysosomal-associated transmembrane protein 4B in hepatitis C virus-induced hepatocellular carcinoma. <i>International Journal of Biological Markers</i> , 2018, 33, 283-292.	0.7	2
68	Antiemetic prophylaxis with temozolomide: an audit from a tertiary care center. <i>Neuro-Oncology Practice</i> , 2019, 6, 479-483.	1.0	2
69	A competing risk analysis of death patterns in male genitourinary cancer. <i>Cancer Reports</i> , 2020, 3, e1174.	0.6	2
70	Identification of key genes and construction of regulatory network for the progression of cervical cancer. <i>Gene Reports</i> , 2020, 21, 100965.	0.4	2
71	A weight function method for selection of proteins to predict an outcome using protein expression data. <i>Journal of Computational and Applied Mathematics</i> , 2021, 391, 113465.	1.1	2
72	Low-cost oral metronomic versus intravenous chemotherapy in recurrent, inoperable and metastatic head and neck cancer: Phase III Metro-CIS study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6506-6506.	0.8	2

#	ARTICLE	IF	CITATIONS
73	Time-Dependent Area under the ROC Curve for Optimum Biological Dose Detection. <i>Turkiye Klinikleri Journal of Biostatistics</i> , 2016, 8, 103-109.	0.1	2
74	Thresholding of prominent biomarkers of breast cancer on overall survival using classification and regression tree. <i>Cancer Biomarkers</i> , 2022, 34, 319-328.	0.8	2
75	Quality of life in patients with locally advanced head and neck squamous cell carcinoma undergoing concurrent chemoradiation with <scp>onceâ€œweek</scp> versus <scp>onceâ€œeveryâ€œweeks</scp> cisplatin. <i>Cancer Medicine</i> , 2022, 11, 3939-3948.	1.3	2
76	RMAC study: A randomized study for evaluation of metronomic adjuvant chemotherapy in recurrent head and neck cancers post salvage surgical resection in those who are ineligible for re-irradiation. <i>Oral Oncology</i> , 2022, 128, 105816.	0.8	2
77	Risk assessment in liver transplantation patients: A shared frailty parametric approach. <i>Clinical Epidemiology and Global Health</i> , 2016, 4, 1-15.	0.9	1
78	Joint modeling of missing and mismeasured measurements for computing radiotherapy margins. <i>Clinical Epidemiology and Global Health</i> , 2017, 5, 124-130.	0.9	1
79	Bayesian relative survival : An illustration with lung cancer patients data. <i>Journal of Statistics and Management Systems</i> , 2017, 20, 325-336.	0.3	1
80	Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?. <i>Chemotherapy Research and Practice</i> , 2017, 2017, 1-4.	1.6	1
81	Handling missingness value on jointly measured time-course and time-to-event data. <i>Communications in Statistics Part B: Simulation and Computation</i> , 2020, , 1-21.	0.6	1
82	Joint modeling of longitudinal and time-to-event data with missing time-varying covariates in targeted therapy of oncology. <i>Communications in Statistics Case Studies Data Analysis and Applications</i> , 2020, 6, 330-352.	0.3	1
83	Risk prediction by Raman spectroscopy for disease-free survival in oral cancers. <i>Lasers in Medical Science</i> , 2021, 36, 1691-1700.	1.0	1
84	The Cure Rate Modeling: An Application with Bayesian approach in Liver Cirrhosis Patients. <i>Journal of Data Science</i> , 2015, 13, 421-442.	0.5	1
85	Evaluating the Performance of Hybrid Capture 2 Test as a Primary Screening Test from Studies Conducted in Low and Middle-Income Country Settings- Special Focus India. <i>Asian Pacific Journal of Cancer Prevention</i> , 2021, 22, 2709-2716.	0.5	1
86	An Algorithm to Define the Optimum Biological Dose of Metronomic Chemotherapy. <i>Biometrical Letters</i> , 2018, 55, 1-15.	0.4	1
87	Agreement analysis between three different short geriatric screening scales in patients undergoing chemotherapy for solid tumors. <i>Journal of Cancer Research and Therapeutics</i> , 2016, 13, 1023-1026.	0.3	1
88	Alternative of clinical end point selection for metronomic studies. <i>IJS Short Reports</i> , 2017, 2, 50.	0.1	1
89	Optimal cumulative cisplatin dose for radio-sensitization in locally advanced head and neck cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, e18553-e18553.	0.8	1
90	Randomized phase 3 open label study of quality of life of patients on Pemetrexed versus Erlotinib as maintenance therapy for advanced non squamous non EGFR mutated non small cell lung cancer. <i>Oncotarget</i> , 2019, 10, 6297-6307.	0.8	1

#	ARTICLE	IF	CITATIONS
91	A tertiary care audit of using abiraterone acetate in patients of metastatic castrate-resistant prostate cancer. South Asian Journal of Cancer, 2020, 09, 23-26.	0.2	1
92	Diclofenac versus tramadol for mucositis related pain in head and neck cancer patients undergoing concurrent chemoradiation – a phase 3 study. Ecancermedicalsecience, 2021, 15, 1318.	0.6	1
93	Population-level Outcomes of Early Thyroid Cancers: A Need to Revisit Current Practice. Rambam Maimonides Medical Journal, 2022, 13, e0008.	0.4	1
94	Time Series Analysis Using Different Forecast Methods and Case Fatality Rate for Covid-19 Pandemic. Regional Science Policy and Practice, 0, , .	0.8	1
95	A cross-sectional audit of distress in patients undergoing adjuvant therapy or follow-up in central nervous system malignancies. Neuro-Oncology Practice, 2019, 6, 305-310.	1.0	0
96	Estimation of Treatment Effect with Missing Observations for Three Arms and Three Periods Crossover Clinical Trials. Annals of Data Science, 2020, 7, 447-460.	1.7	0
97	Bayesian competing risk analysis: An application to nasopharyngeal carcinoma patients data. Computational and Systems Oncology, 2021, 1, e1006.	1.1	0
98	Bayesian Effective Biological Dose Determination in Immunotherapy Response Trial. Annals of Data Science, 0, , 1.	1.7	0
99	Missing data handling technique in joint modeling context. Biomedical Engineering Advances, 2021, 2, 100012.	2.2	0
100	An Application of Bootstrap Regression Method in Age Dependency Structure to the Community. Indian Journal of Public Health Research and Development, 2013, 4, 44.	0.1	0
101	A cross-sectional observation study regarding patients and their physician willingness to wait for driver mutation report in nonsmall-cell lung cancer. Indian Journal of Medical and Paediatric Oncology, 2016, 37, 74-78.	0.1	0
102	Tyrosine kinase inhibitor versus physician choice chemotherapy in second-line epidermal growth factor receptor mutation non-small cell lung cancer: Post hoc analysis of randomized control trial. Indian Journal of Medical and Paediatric Oncology, 2018, 39, 493.	0.1	0
103	QOL assessment in head and neck cancer patients undergoing neoadjuvant chemotherapy and its impact on overall survival.. Journal of Clinical Oncology, 2019, 37, e17519-e17519.	0.8	0
104	Prostate cancer survival estimates: An application with piecewise hazard function derivation. South Asian Journal of Cancer, 2019, 08, 150-159.	0.2	0
105	Impact of early reduction in paraprotein on survival in transplant ineligible myeloma: Lesson from a tertiary cancer center in rural India. Journal of Cancer Research and Therapeutics, 2020, 16, 88.	0.3	0
106	Quality of life in patients with locally advanced head and neck cancer undergoing chemoradiation with once-a-week versus once-every-three-weeks cisplatin.. Journal of Clinical Oncology, 2020, 38, 12092-12092.	0.8	0
107	Long-term outcomes of a randomized controlled clinical trial comparing the efficacy of cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer.. Journal of Clinical Oncology, 2022, 40, e18008-e18008.	0.8	0
108	Phase III randomized control study evaluating adjuvant metronomic chemotherapy in locally advanced head and neck cancers post-radical chemoradiation (MACE-CTRT).. Journal of Clinical Oncology, 2022, 40, 6073-6073.	0.8	0